My elephant that never seems to feature is.... Imbio is projected to generate US$3.0 million in revenue in CY2023 and US$6.3 million in CY2024, with expectations to be cashflow positive within the first year post-integration. The acquisition of Imbio is also likely to strengthen 4DMedical’s efforts in lung screening and other cardiothoracic conditions, by enabling the identification and quantification of early-stage diseases. Alot of shareholder money went into this acquisition and last report they didnt even make the benchmark for milestone payments?? WTF is really going on here. Only in the footnote "About 4DX "Imbio will be acquired for an upfront purchase price of US$25 million (approximately A$38.5 million), plus a contingent earnout including one tranche of up to US$10 million in CY2024 and two tranches of up to US$5 million each in CY2025, all conditional on the achievement of key milestones as outlined in Schedule 1 below." I mean we paid a sh,tton of money for this and does it mean if they can't make the cy2024/2025 milestones we get it for cheap....because it might be a lemon.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)